pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
KEYTRUDA · news · pharmadog
← back to KEYTRUDA
News mentioning KEYTRUDA
219
stories
Oct 11, 26
The 2026 Biotech Graveyard
fiercebiotech
Oct 9, 26
STAT+: Pharma’s free lunches for doctors boost inappropriate prescribing, analysis finds
stat
Oct 9, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Oct 9, 26
STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
stat
Oct 8, 26
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
Oct 8, 26
Merck barred from making subcutaneous Keytruda in 8 European countries
biospace
Oct 8, 26
STAT+: Pharmalittle: We’re reading about PhRMA suing Trump, biotech frustration over tariffs, and more
stat
Oct 8, 26
Recon: FDA identifies four deaths in Newron schizophrenia drug trials; Dutch court blocks subcutaneous Keytruda in eight Europea...
raps
Oct 7, 26
STAT+: In small trial, optogenetics restores some vision lost to retinitis pigmentosa
stat
Oct 7, 26
Dutch court blocks subcutaneous Keytruda in eight European countries
endpoints
Oct 7, 26
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharma dive
Oct 7, 26
STAT+: Merck suffers a setback in Europe over its new Keytruda formulation
stat
Oct 7, 26
5 biggest venture capital raises of Q3 2026
biospace
Oct 5, 26
Significant stock movers of September: Viking soars, Longeveron slides
biospace
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Oct 2, 26
Varda raises $251M to leverage gravity in space for drug production
biospace
Oct 1, 26
Lilly, Foghorn part ways; Wave’s FDA-approved plans
biopharma dive
Sep 29, 26
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
Sep 29, 26
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
fiercebiotech
Sep 28, 26
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
Sep 28, 26
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 25, 26
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
Sep 24, 26
Merck reveals study success, and possible safety worries, for eye drug hopeful
biopharma dive
Sep 24, 26
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
Sep 24, 26
Merck’s return to ophthalmology snags first success
endpoints
Sep 24, 26
Merck sees pivotal victory for $3B eye disease prospect
fiercebiotech
Sep 15, 26
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
Sep 14, 26
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
Sep 14, 26
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
← prev
page 3 of 8
next →